Evidence map›Paper›PMID 34680299›Full record

ArticleCancers2021

Serum Epiplakin Might Be a Potential Serodiagnostic Biomarker for Bladder Cancer.

Soichiro Shimura, Kazumasa Matsumoto, Yuriko Shimizu, Kohei Mochizuki, Yutaka Shiono, Shuhei Hirano, Dai Koguchi, Masaomi Ikeda, Yuichi Sato, Masatsugu Iwamura

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Soichiro ShimuraDepartment of Urology, Kitasato University School of Medicine, Sagamihara Campus, 1-15-1 Kitasato, Sagamihara 252-0374, Kanagawa, Japan.
Kazumasa MatsumotoDepartment of Urology, Kitasato University School of Medicine, Sagamihara Campus, 1-15-1 Kitasato, Sagamihara 252-0374, Kanagawa, Japan.
Yuriko ShimizuDepartment of Urology, Kitasato University School of Medicine, Sagamihara Campus, 1-15-1 Kitasato, Sagamihara 252-0374, Kanagawa, Japan.
Kohei MochizukiInternational University of Health and Welfare Atami Hospital, 13-1 Higashikaigan Town, Atami 413-0012, Shizuoka, Japan.
Yutaka ShionoDepartment of Urology, Kitasato University School of Medicine, Sagamihara Campus, 1-15-1 Kitasato, Sagamihara 252-0374, Kanagawa, Japan.
Shuhei HiranoDepartment of Urology, Kitasato University School of Medicine, Sagamihara Campus, 1-15-1 Kitasato, Sagamihara 252-0374, Kanagawa, Japan.
Dai KoguchiDepartment of Urology, Kitasato University School of Medicine, Sagamihara Campus, 1-15-1 Kitasato, Sagamihara 252-0374, Kanagawa, Japan.
Masaomi IkedaDepartment of Urology, Kitasato University School of Medicine, Sagamihara Campus, 1-15-1 Kitasato, Sagamihara 252-0374, Kanagawa, Japan.
Yuichi SatoDepartment of Urology, Kitasato University School of Medicine, Sagamihara Campus, 1-15-1 Kitasato, Sagamihara 252-0374, Kanagawa, Japan.ORCID 0000-0002-4441-0306
Masatsugu IwamuraDepartment of Urology, Kitasato University School of Medicine, Sagamihara Campus, 1-15-1 Kitasato, Sagamihara 252-0374, Kanagawa, Japan.
Kitasato University · JPInternational University Of Health And Welfare Atami Hospital · JP

Funding

JSPS KAKENHI JP18K09206JSPS KAKENHI JP21K09355
6 · The paper itself

Abstract

Tumor markers that can be detected at an early stage are needed. Here, we evaluated the epiplakin expression levels in sera from patients with bladder cancer (BC). Using a micro-dot blot array, we evaluated epiplakin expression levels in 60 patients with BC, 20 patients with stone disease, and 28 healthy volunteers. The area under the curve (AUC) and best cut-off point were calculated using receiver-operating characteristic (ROC) analysis. Serum epiplakin levels were significantly higher in patients with BC than in those with stone disease (

Indexed as

bladder cancerdiagnosisepiplakinradical cystectomy

Identifiers

PMID34680299
PMCPMC8534213
OpenAlexW3207314304

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.